---
title: "12 Health Care Stocks Moving In Monday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302314681.md"
description: "During Monday's intraday session, several healthcare stocks experienced significant volatility. Gainers included Silence Therapeutics (up 125.6%), SCWorx (up 80.32%), and Disc Medicine (up 40.01%). Conversely, major losers featured EyePoint Pharmaceuticals (down 85.7%) and Matinas BioPharma (down 33.34%). These sharp movements followed recent Q4 earnings reports released four days prior."
datetime: "2026-10-19T17:05:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302314681.md)
  - [en](https://longbridge.com/en/news/302314681.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302314681.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Monday's Intraday Session

### Gainers

-   **Silence Therapeutics** (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million.
-   **SCWorx** (NASDAQ:WORX) stock increased by 80.32% to $2.49.
-   **Disc Medicine** (NASDAQ:IRON) shares moved upwards by 40.01% to $79.58. The market value of their outstanding shares is at $2.1 billion.
-   **CytoSorbents** (NASDAQ:CTSO) shares increased by 20.18% to $4.94. The company's market cap stands at $9.6 million.
-   **Actinium Pharmaceuticals** (AMEX:ATNM) stock increased by 19.05% to $1.35. The market value of their outstanding shares is at $33.2 million.
-   **Advanced Biomed** (NASDAQ:ADVB) stock increased by 18.34% to $4.71. The market value of their outstanding shares is at $7.9 million. As per the news, the Q4 earnings report came out 4 days ago.

### Losers

-   **EyePoint** (NASDAQ:EYPT) shares decreased by 85.7% to $0.43 during Monday's regular session. The company's market cap stands at $270.7 million.
-   **Matinas BioPharma Hldgs** (AMEX:MTNB) stock decreased by 33.34% to $1.58. The company's market cap stands at $35.5 million.
-   **Estrella Immunopharma** (NASDAQ:ESLA) stock fell 29.88% to $0.3. The market value of their outstanding shares is at $23.2 million.
-   **Lunai Bioworks** (NASDAQ:LNAI) shares declined by 26.67% to $0.5. The company's market cap stands at $3.7 million. As per the press release, Q4 earnings came out 4 days ago.
-   **CDT Equity** (NASDAQ:CDT) stock declined by 26.16% to $0.17.
-   **NeuroSense Therapeutics** (NASDAQ:NRSN) shares declined by 22.64% to $2.38. The market value of their outstanding shares is at $6.0 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md)
- [ATNM.US](https://longbridge.com/en/quote/ATNM.US.md)
- [CDT.US](https://longbridge.com/en/quote/CDT.US.md)
- [CTSO.US](https://longbridge.com/en/quote/CTSO.US.md)
- [ESLA.US](https://longbridge.com/en/quote/ESLA.US.md)
- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)
- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)
- [LNAI.US](https://longbridge.com/en/quote/LNAI.US.md)
- [MTNB.US](https://longbridge.com/en/quote/MTNB.US.md)
- [NRSN.US](https://longbridge.com/en/quote/NRSN.US.md)
- [SLN.US](https://longbridge.com/en/quote/SLN.US.md)
- [WORX.US](https://longbridge.com/en/quote/WORX.US.md)

## Related News & Research

- [EyePoint consensus price target decreased by 81.86% to $5.29](https://longbridge.com/en/news/302867212.md)
- [EyePoint Pharmaceuticals (EYPT) was downgraded to a Hold Rating at JonesTrading](https://longbridge.com/en/news/302927797.md)
- [BUZZ-Disc Medicine down after $450 mln equity raise following rare disease drug trial success](https://longbridge.com/en/news/302555358.md)
- [Disc Medicine completes major common stock offering](https://longbridge.com/en/news/302781385.md)
- [Actinium Advances ATNM-400 to Higher Dose in Phase 1 Prostate Cancer Trial](https://longbridge.com/en/news/302419089.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**